Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: EZLibra who wrote (1021)	1/7/1998 8:26:00 PM
From: EZLibra	Read Replies (2) \| Respond to of 3702

Enough phone calls! It's difficult to stop being Techniclone's 'loudest bull'. Hey, call me a seeker of tax losses, a philanthropist, hopeless maybe, but don't call me a bear. The stock situation has been much worse. It's comforting to have others fighting for truth, justice, and the cancer-free way. There are some positives; (1) TCLN will not run out of money, for a price financing is always available and I hear members of the board are willing to provide bridge loans. It's much too early to worry. (2) TCLN has been through this before (I testify as a reformed non-activist). This time the management has besotted themselves with options. They are ready to roll. (3) Many of the brethren, Big Pharma and Big Bio, are on the sidelines, and have been, ready to cherrypick. If the CEO-to-be cannot bridge the credibility gap then I have 1% (until March) I will vote to hire an investment banker to shop the company. I am not alone. Take 3-4 hundred million worth of TCLN science, do a tax-free stock-for-stock, and the right acquirer would increase in value exponentially (it's called p/e). Techniclone science would increase the market cap of Merck. And many, many cancer victims would be helped. Just speculating, of course. Can any of you believe that Lon Stone turned down an American Cyanamid bid of $10 a share (10 million shares) nine years ago? ACY owns 60% of IMNX and was bought by AHP which owns Genetics Institute and is one of the most progressive pharmas. This stock is grossly undervalued. BTW, I have suggested to my phone callers (most of whom want to buy) not to buy until the stock price turns, though they know it doesn't matter in the long run. We've been through this before.